#United States #New York #Investor Conferences #Coya Therapeutics #Treg Biology

Coya Therapeutics to Participate in Upcoming Investor Conferences

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, is gearing up for significant investor engagements this September. The firm is dedicated to innovating biologics that bolster regulatory T cell (Treg) functions, particularly for patients grappling with neurodegenerative conditions. Here’s what to expect from their upcoming appearances.

Conference Details

Coya Therapeutics will participate in two notable investor conferences this month, presenting an opportunity to connect with potential investors, partners, and stakeholders:

1. H.C. Wainwright 27th Annual Global Investment Conference
- Date: September 10, 2025
- Time: 10 AM ET
- Format: Presentation by Dr. Arun Swaminathan, CEO
- Location: Lotte New York Palace Hotel, New York City
- Webcast: Access Here

2. Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
- Date: September 11, 2025
- Location: The Yale Club of New York City

During these conferences, Coya's management team will also be available for one-on-one meetings, giving investors a chance to engage in detailed discussions about the company's innovative research and vision.

About Coya Therapeutics

Headquartered in Houston, Texas, Coya Therapeutics is at the forefront of biotechnology, focusing on developing proprietary treatments which aim to exploit the biology and potential therapeutic advantages of Tregs. These cells are crucial in managing systemic inflammation and neuroinflammation, which are underlying factors in a variety of medical conditions, including neurodegenerative, metabolic, and autoimmune diseases.

Dysfunctional Tregs can lead to persistent inflammation and oxidative stress, disrupting immune system homeostasis. With a strong investigational product candidate pipeline, Coya seeks to restore the anti-inflammatory and immunomodulatory capabilities of Tregs through various therapeutic modalities. These include Treg-enhancing biologics, Treg-derived exosomes, and personalized autologous Treg cell therapy.

Coya’s clinical strategies emphasize not only restoring Treg function but also addressing the intricate dynamics of the immune system, aiming to tackle significant health challenges.

Accessing Webcast and Further Information

Investors interested in the details of Coya's presentation and future prospects can find more resources including live and archived webcasts accessible from their official website, under the Investor Relations section. Importantly, investors will be able to replay the webcast for up to 90 days following the events.

With a clear focus on innovation and investor engagement, Coya Therapeutics is setting the stage for meaningful discussions at this month’s meetings, as they strive to advance their groundbreaking work in biotechnology. The company’s commitment to enhancing Treg function is a pivotal aspect of their mission to address critical health issues concerning neurodegenerative diseases.

As the healthcare landscape continues to evolve, Coya Therapeutics remains dedicated to paving the way toward novel treatments that not only promise therapeutic benefit but also hope for countless patients worldwide. Stay tuned for updates from the conferences as Coya undertakes critical steps in their journey to redefine treatment paradigms in biotechnology.